Answers are grounded in this paper and cite their sources.
Background Targeted therapies are increasingly available for locally aggressive, nonmalignant neoplasms, yet patient preferences remain poorly understood. Tenosynovial giant cell tumor (TGCT) is a locally aggressive mesenchymal neoplasm with multiple therapies and no consensus on frontline systemic treatment. Patients and methods This prospective observational study used a patient survey incorporating a discrete-choice experiment and rank-importance assessment, conducted by TGCT Support from January to March 2026. Treatment attributes included efficacy (tumor response, symptom improvement), adverse events (AEs), and convenience (route, dosing frequency), informed by literature and patient input. Relative importance and trade-offs were estimated using conditional regression models. Results A total of 250 patients were included (median age 46 years, 82.0% female, median disease duration 4.1 years). Patients reported, on average, 2.1 surgeries; 40.4% received systemic therapy (41.6% imatinib, 35.6% vimseltinib, and 31.7% pexidartinib) and 98% reported ≥1 AE, commonly fatigue (89.1%), facial/periorbital edema (64.4%), and pruritus (40.6%). For surgical outcomes, patients prioritized complete resection (54.0%) over symptom relief (34.4%). When complete macroscopic resection was unachievable, systemic therapy was strongly preferred. Among systemic therapies, symptom improvement was prioritized as an efficacy measure (60.4%). Patients preferred greater symptom relief ( P < 0.01), lower AE impact on quality of life (QoL; P < 0.01), and oral administration ( P = 0.04). Symptomatic improvement had the highest relative importance (49.3%), followed by fatigue (17.9%), tumor response (14.2%), and facial edema (11.2%). Patients required 1.9 times, 1.8 times, and 1.2 times the magnitude of the utility associated with the tumor response to offset invasive/disruptive treatment logistics, intravenous administration, and fatigue, respectively. Conclusions In TGCT, shared decision-making and regulatory considerations should prioritize symptoms while minimizing treatment burden and AE-related impacts on QoL.
No takes yet. Share an insight, caveat, or question.
Stern et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: